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Abstract Hematoma puncture and subsequent clot lysis
with recombinant tissue plasminogen activator (rtPA)
emerged as an alternative therapy for spontaneous intrace-
rebral hemorrhage (ICH) and is associated with delayed
edema possibly counteracting the beneficial effects of he-
matoma volume reduction. We hypothesized that immediate
reversal of rtPA activity after clot lysis and hematoma drain-
age diminishes edema formation. To test this hypothesis, we
administered plasminogen activator inhibitor (PAI)-1 after
rtPA lysis of experimentally induced ICH. A right frontal
ICH was placed through a twist drill burr hole and autolo-
gous blood injection. Following creation of the frontal ICH,
pigs received no further treatment (n05), lysis with rtPA
(n07), or lysis with rtPA followed by administration of PAI-1
(n06). Hematoma and edema volumes were assessed with
magnetic resonance imaging on days 0, 4, and 10. The rtPA
significantly reduced hematoma volume and contributed to
edema on day 10 after experimentally induced ICH. Admin-
istration of PAI-1 attenuated the rtPA-induced edema volume
on day 10, but the hematoma volume reduction was less
pronounced. In conclusion, PAI-1 attenuated delayed cerebral
edema after rtPA lysis of experimental ICH but also reduced
the lytic activity of rtPA. The combination of rtPA clot lysis
with PAI-1 might have the potential to further improve the
effect of the lytic therapy of ICH, but additional studies to define
the optimum time point for PAI-1 administration are required.
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Spontaneous intracerebral hematomas (ICH) represent approx-
imately 10% of all strokes and have a 1-year mortality ranging
from 27 to 47% [1–3]. Prospective studies reveal equally poor
outcomes with either surgery or medical management of ICH
[4], though a subset of patients with lobar ICH may benefit
from the former [5].
Stereotactic puncture and clot aspiration have been con-
sidered as an alternative to craniotomy and (micro-) surgical
clot removal, with the advantage of avoidance of general
anesthesia, decreased surgical time, and diminished opera-
tive blood loss [6]. To enhance the amount of hematoma
removal, frame-based and frameless stereotactic puncture
and aspiration were combined with urokinase or recombi-
nant tissue plasminogen activator (rtPA)-induced clot lysis
and subsequent drainage in animal [7, 8] and human studies
[9, 10].
Despite a reduction in hematoma volume, delayed edema
formation peaking at day 10 was seen in pigs with rtPA-
lysed experimental ICH [11]. This edema might limit the
benefit of rtPA clot lysis when compared to clot evacuation
without lysis [7, 12, 13]. We hypothesized that immediate
reversal of rtPA activity after clot lysis and evacuation
would diminish such toxicity. To test this hypothesis, we
administered plasminogen activator inhibitor (PAI)-1 after




A well-established porcine model of ICH was used for the
study [14]. All procedures were performed in accordance
with the institutional guidelines for animal welfare and
experimental conduct of the University of Göttingen under
a protocol approved by the regulatory agencies of Lower
Saxony, Germany (33.42502/§9-004/07).
Deutsche Landrasse male pigs of 30–35 kg were sedated
with ketamine (10–15 mg/kg IM) and azaperone (7 to
10 mg/kg) to allow placement of a venous line. Pentobarbi-
tal 15–20 mg/kg IV, ketamine (1–2 mg/kg IV), and propofol
were then administered, and intubation was performed. Res-
piratory rate and tidal volume were adjusted to maintain
physiological end-tidal CNO2 (PEEP, 3–5 mmHg I/E 1:2;
TV, 500 ml).
A femoral arterial line was placed, and the animal was
prepared and draped for surgery. A straight sagittal midline
incision was made, and the bregma was exposed. A 3.97-mm
twist drill burr hole was placed 0.7 cm right of midline and
1.7 cm anterior to the coronal suture. The tip of a 6-French
EMB80 Fogarty balloon catheter (Edwards Lifesciences,
Irvine, CA, USA) was introduced to a depth of 1 cm
into the right frontal lobe, and the balloonwas inflated for 2 s. A
1.2-cm catheter with an attached reservoir (McCombs catheter,
Valley Forge, PA, USA) was then placed into the preformed
cavity.
Autologous arterial blood from the femoral line was
slowly injected through the reservoir and catheter into the
right frontal lobe by using a modified double-injection
method (2 ml blood, pause of 1 min, 5 ml blood) to prevent
substantial blood reflux along the catheter into the subdural
compartment. Skin closure was performed. The pigs were
then taken for MRI under propofol sedation and ventilation
with room air.
Magnetic Resonance Imaging
MRI was performed immediately after surgery (day 0)
and on days 4 and 10 using a 3.0-T MR imaging system
(Magnetom Trio, Siemens Medicals Solutions, Erlangen,
Germany) with a standard birdcage head coil. The in-plane
resolution was 1.2 by 1.0 mm for T2*, 1.4 by 1.1 mm for
FLAIR, 1.8 by 1.8 mm for diffusion, and 0.6 by 0.6 mm for
dual weighted echo. The hematoma volume was calculated on
T2* images and the edema volume on FLAIR images [15].
Using the MR imaging software (Syngo, Siemens Medicals
Solutions, Erlangen, Germany), the areas of hemorrhage and
edemawere traced directly on the viewing screen for each slice,
and the volume was calculated by a formula of Kothari [16].
The length and equatorial diameter and the number of MRI
slices were multiplied and divided by 2(V0A×B×C/2) [16].
Fibrinolytic and Plasminogen Activator Inhibitor-1 Therapy
The rtPA (Actilyse, Boehringer Ingelheim, Germany) pow-
der was reconstituted with sterile water to a concentration of
1 mg/ml. Dosage was calculated by multiplying the maxi-
mum diameter of the clot (in millimeters) with 0.1 mg rtPA
[17]. Immediately after imaging, the rtPA and rtPA–PAI-1
group animals were returned to the operating room for
fibrinolytic therapy. The wound was again prepared and
draped, and partially reopened to enable clear visualization
of the reservoir for rtPA injection. Corresponding to the
short half-life of rtPA, the reservoir was re-punctured after
15 min to aspirate the lysed hematoma. The aspiration was
performed carefully over 2 min in the treated animals but
not in the control group.
PAI-1 (Oxford Biomedical Research, Rochester Hills,
MI, USA) was resuspended in normal saline to a final
concentration of 1.1 mg/ml and injected into the reservoir
directly after aspiration of the hematoma. In all pigs, the
reservoir and catheter were left in place, and the wound was
again closed. Five pigs, in which only a hematoma was
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created, served as a control group. In seven pigs, fibrinolytic
therapy without PAI-1 (rtPA group), and in six pigs, fibri-
nolytic therapy with additional PAI-1 injection (rtPA–PAI-1
group) were performed.
The hematoma and edema volumes are expressed as
mean values ± SD, and the statistical evaluation was




The mean hematoma volume was 3.84 ml (±2.4 ml) in the
control group, 3.7 ml (±2.65 ml) in the rtPA group, and
3.5 ml (±2.65 ml) in the rtPA–PAI-1 group directly after
surgery. On day 4, the mean hematoma volume dropped to
3.01 ml (±2.02 ml) in the control group, to 2.42 ml
(±2.02 ml) in the rtPA group, and to 2.46 ml (±1.28 ml) in
the rtPA–PAI-1group. On day 10, a further reduction of the
hematoma volume could be seen. The hematoma volume
was 2.62 ml (±0.87 ml) in the control group, 1.36 ml
(±1.12 ml) in the rtPA group, and 2.12 ml (±0.98 ml) in
the rtPA–PAI-1 group.
The mean volume reduced by aspiration 15 min after
lysis was 0.97 ml (±1 ml) in the rtPA group and 1.2 ml
(±1.5 ml) in the rtPA–PAI-1 group. The overall hemato-
ma volume reduction was 31.8 % in the control group,
63.3 % in the rtPA group, and 39.5 % in the rtPA–PAI-1
group. Compared to the control group, the hematoma
volume reduction was significantly higher (p00.034) in
the rtPA group, whereas the hematoma volume reduction
in the rtPA–PAI-1 group showed no significant difference
(Fig. 1).
Cerebral Edema
The mean edema volume on day 0 was 0.91 ml (±2.82 ml) in
the control group, 0.53 ml (±0.62 ml) in the rtPA group, and
2.46 ml (±3.72 ml) in the rtPA–PAI-1 group. On day 4, an
edema volume of 14.82 ml (±9.45 ml) in the control group,
17.37ml (±8.2ml) in the rtPA group, and 24.62ml (±11.21ml)
in the rtPA–PAI-1group was measured. On day 10, the edema
volume had dropped to 12.9 ml (±11.15 ml) in the control
group and to 11.94 ml (±11.93 ml) in the rtPA–PAI-1 group,
whereas in the rtPA group, a further increase to 30.94 ml
(±16.02 ml) was seen.
The overall edema volume increase was 1,411 % in the
control group, 5,937 % in the rtPA group, and 485 % in the
rtPA–PAI-1 group. On day 4, differences in the amount of
edema were not significant among the treatment groups.
Student's t test demonstrated significant differences in ede-
ma volume on day 10 between the control and the rtPA
group (p00.05) and again at day 10 between the rtPA and
the rtPA–PAI-1 groups (p00.032) (Fig. 2).
Discussion
Clinical series have demonstrated that fibrinolytic therapy
after stereotactic puncture allows reducing the volume of a
spontaneous ICH by 60 to 70 %. In most of these clinical
studies, the mortality rates had been lower in comparison to a
series of (micro-)surgical clot removal or best medical therapy,
which was believed to be the result of effective volume
Fig. 1 Mean hematoma
volume of each group at day 0
and 10 with SD bars. There is a
significant decrease in
hematoma volume in the rtPA
group (n07) compared to the
control group (n05). The
rtPA–PAI-1 group (n06) shows
a not significant decrease of
hematoma volume
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reduction despite the minimal invasiveness of the procedure.
However, in the only available randomized trial, comparing
fibrinolytic therapy with conservative management, a positive
effect of stereotaxy and clot lysis on outcome could not been
demonstrated [18]. Animal experiments have indicated that
rtPA is effective in reducing the hematoma volume but is
accompanied by a delayed perihematomal edema [19–22]. It
seems possible that the occurrence of the delayed edema
attenuates or eliminates the positive effect of accelerated clot
lysis by rtPA on outcome and may explain the equivocal
clinical results [11].
Perihematomal Edema
The present experimental study confirms again the observa-
tions that fibrinolytic therapy in experimental ICH induces
delayed perihematomal edema. There are several explana-
tions for the occurrence of the delayed edema. (1) In vitro
mouse neuronal cultures showed that endogenous tPA medi-
ates microglial activation and excitotoxic neuronal degener-
ation [23, 24]. In line with this finding, mice deficient in tPA
have reduced edema compared to wild-type mice after brain
injury and focal cerebral ischemia [25]. As hypoperfusion
Fig. 2 Mean edema volumes of each group are shown at day 4 and 10 with SD bars. A significant difference was seen between the rtPA (n07) and
rtPA–PAI-1 group (n06)
Fig. 3 Coronal MR–FLAIR images of one animal in each group (a, b, c) in the upper lane immediately after surgery at day 0 and in the lower lane
at day 10. The red arrows indicate ICH, and the blue arrows indicate edema
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and ischemia occur in the penumbra of the intracerebral
hematoma, adding exogenous tPA as in fibrinolytic therapy
for ICH probably enhances these processes leading to ede-
ma formation. Accordingly, we have been able to show in a
recent animal experiment that the late edema after experi-
mental clot lysis could be reduced using MK 801 for block-
age of the excitotoxicity-mediating NMDA receptors [26].
(2) Furthermore, at least one study showed that direct injec-
tion of rtPA into the rat brain is neurotoxic [21], possibly
partly mediated via compromise of the blood–brain barrier
[27]. (3) Thrombin, which is inhibited by PAI-1, is one of
the major sources of perihematomal edema [28]. The intra-
cerebral concentration of PAI-1 after experimental ICH in
rats is significantly higher in the perihematomal brain tissue
compared to the contralateral hemisphere [29], possibly
indicating that the attempt is made to control the increased
thrombin release after ICH. The rtPA likewise is inhibited
by PAI-1. If not compensated by the upregulation of endog-
enous PAI-1, the administration of rtPA during fibrinolytic
therapy reduces the relative concentration of PAI-1 available
for thrombin inactivation, thus leading to edema.
Rationale for PAI-1 Therapy
The occurrence of a delayed perihematomal edema after
fibrinolytic therapy, as seen in our previous and this study,
indicates that the increase of endogenous PAI-1 fails to
prevent higher thrombin concentrations. Therefore, we hy-
pothesized that exogenous PAI-1, given after tPA-lysis,
attenuates edema formation by inhibiting both thrombin
and exogenous rtPA. The finding of the study proved the
hypothesis to be correct, as the perihematomal edema was
significantly lower in the rtPA–PAI-1 than in the rtPA group.
Furthermore, administration of a hexapeptide mimicking the
action of PAI-1 was neuroprotective in rat stroke models
[30]. In vitro experiments in neural differentiated pheochro-
mocytoma cells indicated an additional anti-apoptotic effect
of PAI-1 [31]. Possibly, these direct neuroprotective effects
of PAI-1 contributed to the documented edema reduction.
Clot Lysis and PAI-1
The present experiment showed that injection of PAI-1 after
rtPA clot lysis and aspiration of the liquefied blood attenuates
not only formation of the delayed edema but also reduction of
the clot volume. The positive effect of edema volume reduc-
tion might be decreased by less effective hematoma volume
reduction. Hematoma and edema volume reduction is neces-
sary for optimal clinical outcome. In this setting, the timing of
rtPA administration and clot aspiration was corresponded to
its short half time of about 20 min. Expecting a sufficient clot
reduction after lysis and aspiration, PAI-1 was administered
immediately after clot aspiration. In contrast to our previous
findings [7], there is a progressive decrease of the hematoma
volume from day 0 to 10 in the rtPA group (Fig. 3). Probably,
this suggests an ongoing clot lysis after aspiration or could
also be drainage of liquefied clot into the subdural space. An
ongoing effect might be interrupted by the administration of
PAI-1. Future experimental studies should focus on definition
of the optimum PAI-1 administration time point to achieve
both maximum clot lysis by rtPA and avoidance of edema
formation. If this time point is identified, the combination of
rtPA and PAI-1 compared to single rtPA in the fibrinolytic
therapy of intracerebral hemorrhage has the potential to im-
prove the clinical results.
Conclusion
PAI-1 not only diminishes cerebral edema after rtPA treat-
ment of experimental ICH in pigs but also attenuates the
hematoma lysis by rtPA. We propose that the time point of
administration of PAI-1 after rtPA lysis needs further inves-
tigation and can lead to a more neuroprotective and effective
rtPA therapy of ICHs.
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